HER-2-pulsed DCs have been reported to show clinical benefits in patients bearing HER-2-positive breast cancer, reaching nearly 20% complete elimination of disease or, in the presence of residual cancers, repression of HER-2 expression [116]. This evidence concerns the gene ERBB2 and breast carcinoma.